01/04/2026 06:00
|
Medical, Health & Aged Care
As CSL’s first monoclonal antibody discovered and developed in-house by CSL scientists, ANDEMBRY® will be available on the Pharmaceutical Benefits Scheme from April 1, 2026.
ANDEMBRY® is a...